Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
Subscribe To Our Newsletter & Stay Updated
